

Wh Wilson Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6384285/publications.pdf>

Version: 2024-02-01

729
papers

69,186
citations

1793

106
h-index

1040

242
g-index

872
all docs

872
docs citations

872
times ranked

62441
citing authors

#	ARTICLE	IF	CITATIONS
1	Supra-normal left ventricular ejection fraction in cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2023, 112, 441-443.	1.5	2
2	Comprehensive echocardiographic evaluation of the right heart in patients with pulmonary vascular diseases: the PVDOMICS experience. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 958-969.	0.5	6
3	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. <i>Cardiovascular Research</i> , 2022, 118, 2367-2384.	1.8	45
4	OUP accepted manuscript. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, , .	0.4	2
5	Differential expression of members of SOX family of transcription factors in failing human hearts. <i>Translational Research</i> , 2022, 242, 66-78.	2.2	6
6	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	2.9	23
7	Contemporary Trends of Clinical Outcomes in Primary Left Ventricular Assist Device Implantation and Postprocedure High-Risk Categories. <i>Journal of Cardiac Failure</i> , 2022, 28, 270-282.	0.7	1
8	Intestinal barrier dysfunction is associated with elevated right atrial pressure in patients with advanced decompensated heart failure. <i>American Heart Journal</i> , 2022, 245, 78-80.	1.2	6
9	Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab. <i>JACC Basic To Translational Science</i> , 2022, 7, 1-10.	1.9	2
10	Circulating trimethylamine N-oxide levels following fish or seafood consumption. <i>European Journal of Nutrition</i> , 2022, 61, 2357-2364.	1.8	14
11	Artificial Intelligence and Cardiovascular Genetics. <i>Life</i> , 2022, 12, 279.	1.1	13
12	Characterization of cardiac amyloidosis using cardiac magnetic resonance fingerprinting. <i>International Journal of Cardiology</i> , 2022, 351, 107-110.	0.8	9
13	Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 603-619.	2.9	57
14	The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON-CRT trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1106-1113.	2.9	14
15	Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008877.	1.6	10
16	The microbial gbu gene cluster links cardiovascular disease risk associated with red meat consumption to microbiota l-carnitine catabolism. <i>Nature Microbiology</i> , 2022, 7, 73-86.	5.9	36
17	TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study. <i>Genetics in Medicine</i> , 2022, 24, 1495-1502.	1.1	5
18	Individual sentiments on telehealth in the COVID-19 era: Insights from Twitter. <i>Progress in Cardiovascular Diseases</i> , 2022, 71, 100-102.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Burden of Pediatric Heart Failure in the United States. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1917-1928.	1.2	13
20	Targeting Myocardial Substrate Metabolism in the Failing Heart: Ready for Prime Time?. <i>Current Heart Failure Reports</i> , 2022, 19, 180-190.	1.3	11
21	Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation. <i>Circulation: Cardiovascular Imaging</i> , 2022, 15, e013829.	1.3	2
22	Association of Trimethylamine N-Oxide and Metabolites With Mortality in Older Adults. <i>JAMA Network Open</i> , 2022, 5, e2213242.	2.8	13
23	Usefulness of Serum Biomarkers of Endothelial Glycocalyx Damage in Prognosis of Decompensated Patients with Heart Failure with Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2022, 176, 73-78.	0.7	3
24	Durable Mechanical Circulatory Support in Adult Congenital Heart Disease: Reviewing Clinical Considerations and Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 3200.	1.0	4
25	Diagnostics and Prevention: Landscape for Technology Innovation in Precision Cardiovascular Medicine. , 2022, , 603-624.		0
26	FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling. <i>JCI Insight</i> , 2022, 7, .	2.3	4
27	Magnetic resonance imaging of cardiac metabolism in heart failure: how far have we come?. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1277-1289.	0.5	2
28	Relation of Statin Use to Gut Microbial Trimethylamine N-Oxide and Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2022, 178, 26-34.	0.7	6
29	Stable isotope dilution mass spectrometry quantification of hydrogen sulfide and thiols in biological matrices. <i>Redox Biology</i> , 2022, 55, 102401.	3.9	10
30	Association of Visit-to-Visit Variability in Kidney Function and Serum Electrolyte Indexes With Risk of Adverse Clinical Outcomes Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 68-77.	3.0	12
31	Association Between Egg Consumption and Risk of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2021, 134, 76-83.e2.	0.6	30
32	Cardiac magnetic resonance fingerprinting: Trends in technical development and potential clinical applications. <i>Progress in Nuclear Magnetic Resonance Spectroscopy</i> , 2021, 122, 11-22.	3.9	10
33	Cystatin C and Muscle Mass in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 48-56.	0.7	10
34	Intrarenal Venous Flow: A Distinct Cardiorenal Phenotype or Simply a Marker of Venous Congestion?. <i>Journal of Cardiac Failure</i> , 2021, 27, 35-39.	0.7	5
35	Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154457.	1.5	62
36	Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 152, 105-117.	0.9	58

#	ARTICLE	IF	CITATIONS
37	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	0.7	4
38	Long-Term Outcomes in Patients With a Left Ejection Fraction $\leq 15\%$ Undergoing Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 36-46.	1.3	7
39	Future Therapies in HFpEF. , 2021, , 489-494.		0
40	Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope?. <i>Current Heart Failure Reports</i> , 2021, 18, 23-32.	1.3	11
41	Mitochondrial DNA Content Is Linked to Cardiovascular Disease Patient Phenotypes. <i>Journal of the American Heart Association</i> , 2021, 10, e018776.	1.6	11
42	Identifying sodium \leq non \leq excretors: heart failure's emerging golden ticket for risk stratification. <i>European Journal of Heart Failure</i> , 2021, 23, 740-742.	2.9	0
43	Loop Diuretics Inhibit Renal Excretion of Trimethylamine N-Oxide. <i>JACC Basic To Translational Science</i> , 2021, 6, 103-115.	1.9	7
44	Whole-Transcriptome Profiling of Human Heart Tissues Reveals the Potential Novel Players and Regulatory Networks in Different Cardiomyopathy Subtypes of Heart Failure. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003142.	1.6	7
45	Consensus conference on heart-kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 2459-2467.	2.6	49
46	Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. <i>European Heart Journal</i> , 2021, 42, 919-933.	1.0	113
47	Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. <i>Journal of Cardiac Failure</i> , 2021, 27, 368-372.	0.7	12
48	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
49	Recent advances in the diagnosis and management of amyloid cardiomyopathy. <i>Faculty Reviews</i> , 2021, 10, 31.	1.7	4
50	Egg Consumption and Risk of Cardiovascular Disease: a Critical Review. <i>Current Emergency and Hospital Medicine Reports</i> , 2021, 9, 25-37.	0.6	3
51	Invasive Hemodynamic and Metabolic Evaluation of HFpEF. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	7
52	Relation of Malnutrition to Outcome Following Orthotopic Heart Transplantation. <i>American Journal of Cardiology</i> , 2021, 142, 156-157.	0.7	4
53	Novel Approach to Risk Stratification in Left Ventricular Non \leq Compaction Using A Combined Cardiac Imaging and Plasma Biomarker Approach. <i>Journal of the American Heart Association</i> , 2021, 10, e019209.	1.6	12
54	The IgG3 subclass of β 21-adrenergic receptor autoantibodies is an endogenous biaser of β 21AR signaling. <i>Molecular Biology of the Cell</i> , 2021, 32, 622-633.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Carbohydrate antigen 125 in heart failure: congestive kidneys or beyond?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 484-486.	0.4	0
56	Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside. <i>Journal of Cardiac Failure</i> , 2021, 27, 1053-1060.	0.7	4
57	New Advances and Ongoing Challenges in the Use of Biologic Agents in Cardiac Sarcoidosis and Other Inflammatory Cardiomyopathies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	1
58	Fish Consumption and Cardiovascular Health: A Systematic Review. <i>American Journal of Medicine</i> , 2021, 134, 713-720.	0.6	24
59	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. <i>Circulation: Heart Failure</i> , 2021, 14, .	1.6	11
60	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. <i>American Heart Journal</i> , 2021, 236, 80-86.	1.2	35
61	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	0.7	16
62	Impact of Cardiac Resynchronization Therapy on Global and Cardiac Metabolism and Cardiac Mitochondrial Function. <i>Journal of Cardiac Failure</i> , 2021, 27, 706-715.	0.7	1
63	The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial. <i>European Heart Journal</i> , 2021, 42, 4905-4914.	1.0	60
64	A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device. <i>ESC Heart Failure</i> , 2021, 8, 4353-4356.	1.4	7
65	Dynamic Assessment of Pulmonary Artery Pulsatility Index Provides Incremental Risk Assessment for Early Right Ventricular Failure After Left Ventricular Assist Device. <i>Journal of Cardiac Failure</i> , 2021, 27, 777-785.	0.7	18
66	Evidence of Stability in Patient-Reported Global Health During the COVID-19 Pandemic. <i>Value in Health</i> , 2021, 24, 1578-1585.	0.1	8
67	The Reply. <i>American Journal of Medicine</i> , 2021, 134, e466.	0.6	0
68	Cardiac risk stratification in cancer patients: A longitudinal patient-network analysis. <i>PLoS Medicine</i> , 2021, 18, e1003736.	3.9	19
69	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 721333.	1.1	14
70	Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 171.	2.7	10
71	Longitudinal Plasma Measures of Trimethylamine N-Oxide and Risk of Atherosclerotic Cardiovascular Disease Events in Community-Based Older Adults. <i>Journal of the American Heart Association</i> , 2021, 10, e020646.	1.6	39
72	Three Healthy Eating Patterns and Cardiovascular Disease Risk Markers in 9 to 18 Year Olds With Body Mass Index $\geq 95\%$: A Randomized Trial. <i>Clinical Pediatrics</i> , 2021, 60, 474-484.	0.4	10

#	ARTICLE	IF	CITATIONS
73	Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	13
74	Dietary Choline Supplements, but Not Eggs, Raise Fasting TMAO Levels in Participants with Normal Renal Function: A Randomized Clinical Trial. <i>American Journal of Medicine</i> , 2021, 134, 1160-1169.e3.	0.6	13
75	Modulating gut microbial metabolism in heart failure: Opportunities and challenges. <i>EBioMedicine</i> , 2021, 71, 103573.	2.7	0
76	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. <i>Heart</i> , 2021, , heartjnl-2020-318333.	1.2	3
77	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	1.2	3
78	Renal sodium avidity, the prevailing renal target in heart failure. <i>European Heart Journal</i> , 2021, 42, 4478-4481.	1.0	8
79	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veteransâ€™ Health Administrative Database. <i>CardioRenal Medicine</i> , 2021, 11, 226-236.	0.7	5
80	The Reply. <i>American Journal of Medicine</i> , 2021, 134, e532.	0.6	0
81	Digital Health Applications in Heart Failure: a Critical Appraisal of Literature. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 12.	0.4	21
82	MicroRNAâ€574 regulates FAM210A expression and influences pathological cardiac remodeling. <i>EMBO Molecular Medicine</i> , 2021, 13, e12710.	3.3	21
83	Metabolic endophenotype associated with right ventricular glucose uptake in pulmonary hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	5
84	Fecal Microbiome Composition Does Not Predict Dietâ€Induced TMAO Production in Healthy Adults. <i>Journal of the American Heart Association</i> , 2021, 10, e021934.	1.6	14
85	Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
86	Managing Cancer Patients and Survivors With Advanced Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	0
87	Phenomapping a Novel Classification System for Patients With Destination Therapy Left Ventricular Assist Devices. <i>American Journal of Cardiology</i> , 2021, , .	0.7	2
88	Targeting the Lymphatic System for Interstitial Decongestion. <i>JACC Basic To Translational Science</i> , 2021, 6, 882-884.	1.9	2
89	Medical management of acute heart failure. <i>Faculty Reviews</i> , 2021, 10, 82.	1.7	6
90	Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 101-107.	0.7	26

#	ARTICLE	IF	CITATIONS
91	Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 125, 251-257.	0.7	8
92	Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis. European Journal of Heart Failure, 2020, 22, 148-158.	2.9	169
93	Evaluation of kidney function throughout the heart failure trajectory—A position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	2.9	213
94	Reappraisal of Inflammatory Biomarkers in Heart Failure. Current Heart Failure Reports, 2020, 17, 9-19.	1.3	21
95	Validation of the Larissa Heart Failure Risk Score for risk stratification in acute heart failure. International Journal of Cardiology, 2020, 307, 119-124.	0.8	7
96	Quantification of bile acids: a mass spectrometry platform for studying gut microbe connection to metabolic diseases. Journal of Lipid Research, 2020, 61, 159-177.	2.0	42
97	Relationship Between the Transmural Dispersion of Repolarization and Volume Overload in Heart Failure. Journal of Cardiac Failure, 2020, 26, 93-94.	0.7	1
98	Regulation of Na/K-ATPase expression by cholesterol: isoform specificity and the molecular mechanism. American Journal of Physiology - Cell Physiology, 2020, 319, C1107-C1119.	2.1	8
99	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2020, 13, e007424.	1.6	1
100	Machine learning prediction in cardiovascular diseases: a meta-analysis. Scientific Reports, 2020, 10, 16057.	1.6	182
101	Temporal Trends of Cardiac Outcomes and Impact on Survival in Patients With Cancer. American Journal of Cardiology, 2020, 137, 118-124.	0.7	4
102	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
103	Machine Learning-Based Risk Assessment for Cancer Therapy-Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients. Journal of the American Heart Association, 2020, 9, e019628.	1.6	33
104	Does Weight Loss Improve Clinical Outcomes in Overweight and Obese Patients with Heart Failure?. Current Diabetes Reports, 2020, 20, 75.	1.7	11
105	Impact of timing of atrial fibrillation, CHA2DS2-VASc score and cancer therapeutics on mortality in oncology patients. Open Heart, 2020, 7, e001412.	0.9	3
106	Evidence of Clonal Hematopoiesis and Risk of Heart Failure. Current Heart Failure Reports, 2020, 17, 271-276.	1.3	4
107	Multimodal analgesia using opioid-sparing regimen in patients undergoing left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2020, 39, 977-979.	0.3	3
108	Association between chocolate consumption and risk of coronary artery disease: a systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, , 204748732093678.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Digoxin Use in Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2020, 133, 134-138.	0.7	20
110	Virtual Versus In-Person Visits and Appointment No-Show Rates in Heart Failure Care Transitions. <i>Circulation: Heart Failure</i> , 2020, 13, e007119.	1.6	25
111	Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers. <i>ESC Heart Failure</i> , 2020, 7, 3049-3058.	1.4	3
112	Measures of Loop Diuretic Efficiency and Prognosis in Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2020, 10, 402-414.	0.7	2
113	Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure. <i>Circulation</i> , 2020, 142, 1055-1058.	1.6	9
114	Misinformation Dissemination in Twitter in the COVID-19 Era. <i>American Journal of Medicine</i> , 2020, 133, 1367-1369.	0.6	37
115	Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances. <i>Current Cardiology Reports</i> , 2020, 22, 143.	1.3	9
116	Nonlethal Inhibition of Gut Microbial Trimethylamine N-Oxide Production Improves Cardiac Function and Remodeling in a Murine Model of Heart Failure. <i>Journal of the American Heart Association</i> , 2020, 9, e016223.	1.6	61
117	Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. <i>JAMA Network Open</i> , 2020, 3, e204296.	2.8	32
118	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2020, 26, 727-732.	0.7	7
119	Global analysis of histone modifications and long-range chromatin interactions revealed the differential cistrome changes and novel transcriptional players in human dilated cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 145, 30-42.	0.9	11
120	Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1239-1255.	1.1	102
121	Variant Interpretation for Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002480.	1.6	70
122	A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors. <i>Cell</i> , 2020, 180, 862-877.e22.	13.5	397
123	Artificial Intelligence and Hypertension: Recent Advances and Future Outlook. <i>American Journal of Hypertension</i> , 2020, 33, 967-974.	1.0	17
124	Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis. <i>Circulation Research</i> , 2020, 127, 827-846.	2.0	51
125	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006827.	1.6	15
126	Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. <i>Journal of the American Heart Association</i> , 2020, 9, e016203.	1.6	3

#	ARTICLE	IF	CITATIONS
127	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e006363.	1.6	27
128	Cardiovascular Volume Reserve in Patients with Heart Failure and Reduced Ejection Fraction. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 519-527.	1.1	4
129	Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 199-208.	1.9	59
130	HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans. <i>Heart</i> , 2020, 106, 147-153.	1.2	20
131	Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. <i>Journal of the American Heart Association</i> , 2020, 9, e014708.	1.6	94
132	Epithelial and Endothelial Adhesion of Immune Cells Is Enhanced by Cardiotonic Steroid Signaling Through Na ⁺ /K ⁺ ATPase. <i>Journal of the American Heart Association</i> , 2020, 9, e013933.	1.6	9
133	Myeloperoxidase: a potential therapeutic target for coronary artery disease. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 695-705.	1.5	20
134	Spirolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1451-1461.	2.9	12
135	Right Heart Failure and Cardiorenal Syndrome. <i>Cardiology Clinics</i> , 2020, 38, 185-202.	0.9	25
136	Withdrawal of Neurohumoral Blockade After Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1426-1438.	1.2	21
137	Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES). <i>Tj ETQq1 1 0,784314 rgBT /Over</i>	0.7	38
138	A means to an end: the promise of tracking natriuresis with diuretic therapy. <i>European Journal of Heart Failure</i> , 2020, 22, 1448-1450.	2.9	0
139	RNA Sequence Analyses throughout the Course of Mouse Cardiac Laminopathy Identify Differentially Expressed Genes for Cell Cycle Control and Mitochondrial Function. <i>Scientific Reports</i> , 2020, 10, 6632.	1.6	10
140	Durable Mechanical Circulatory Support in Patients With Amyloid Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2020, 13, e007931.	1.6	15
141	Familial hypercholesterolemia: Detect, treat, and ask about family. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 109-120.	0.6	12
142	Heart Failure in a Patient with End-Stage Kidney Disease on Renal Replacement Therapy. , 2020, , 107-120.		0
143	The role of cardiac imaging in hospitalized COVID-19 positive patients. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	1
144	Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Interdisciplinary Medicine</i> , 2020, 5, 35-42.	0.1	1

#	ARTICLE	IF	CITATIONS
145	In Reply: Familial hypercholesterolemia: Clarifications. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 320.2-320.	0.6	0
146	Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES. <i>ESC Heart Failure</i> , 2020, 7, 4390-4393.	1.4	1
147	Do Natriuretic Peptide Measurements Provide Insights into Management of End-Stage Renal Disease Patients Undergoing Dialysis?. <i>Current Heart Failure Reports</i> , 2020, 17, 449-456.	1.3	1
148	Insights from Twitter about novel COVID-19 symptoms. <i>European Heart Journal Digital Health</i> , 2020, 1, 4-5.	0.7	7
149	Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. <i>IJC Heart and Vasculature</i> , 2020, 30, 100634.	0.6	8
150	Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction. <i>Translational Research</i> , 2019, 212, 80-88.	2.2	10
151	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 36-51.	1.2	37
152	Implications of renin-angiotensin system blocker discontinuation in acute decompensated heart failure with systolic dysfunction. <i>Clinical Cardiology</i> , 2019, 42, 1010-1018.	0.7	6
153	Can saline repletion be the true TARGET for achieving fluid balance in acute heart failure?. <i>European Journal of Heart Failure</i> , 2019, 21, 1090-1092.	2.9	0
154	Initiation of Angiotensin Receptor-Nepilysin Inhibitor in Heart Failure With Low Cardiac Output. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2326-2327.	1.2	9
155	Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 1707-1711.	0.7	11
156	Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT. <i>European Journal of Heart Failure</i> , 2019, 21, 634-642.	2.9	42
157	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. <i>Nature Communications</i> , 2019, 10, 2760.	5.8	22
158	Hemodynamic Determinants of Right Heart Failure are Associated with Impaired T Cell Activation in Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 774-775.	0.7	1
159	Renal Effects of Intensive Volume Removal in Heart Failure Patients With Preexisting Worsening Renal Function. <i>Circulation: Heart Failure</i> , 2019, 12, e005552.	1.6	43
160	Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. <i>European Journal of Heart Failure</i> , 2019, 21, 1415-1422.	2.9	70
161	Genetic Determinants of Circulating Glycine Levels and Risk of Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e011922.	1.6	20
162	Natriuretic Response Is Highly Variable and Associated With 6-Month Survival. <i>JACC: Heart Failure</i> , 2019, 7, 383-391.	1.9	51

#	ARTICLE	IF	CITATIONS
163	Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 404-414.	1.9	42
164	Implications of Perceived Dyspnea and Global Well-Being Measured by Visual Assessment Scales During Treatment for Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2019, 124, 402-408.	0.7	3
165	Intestinal Microbiota in Cardiovascular Health and Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2089-2105.	1.2	301
166	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. <i>European Heart Journal</i> , 2019, 40, 2700-2709.	1.0	79
167	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
168	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
169	Circulating NT-proBNP but not soluble corin levels were associated with preeclampsia in pregnancy-associated hypertension. <i>Clinical Biochemistry</i> , 2019, 67, 12-15.	0.8	8
170	How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology. <i>Personalized Medicine</i> , 2019, 16, 87-92.	0.8	18
171	Deep learning for cardiovascular medicine: a practical primer. <i>European Heart Journal</i> , 2019, 40, 2058-2073.	1.0	218
172	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619
173	Following the Scent of Microbes Within: The Heart-Gut Connection. <i>Journal of Cardiac Failure</i> , 2019, 25, 328-329.	0.7	2
174	Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 693-695.	2.9	3
175	Impact of bariatric surgery on heart failure mortality. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 1189-1196.	1.0	26
176	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
177	Systematic Error Removal Using Random Forest for Normalizing Large-Scale Untargeted Lipidomics Data. <i>Analytical Chemistry</i> , 2019, 91, 3590-3596.	3.2	163
178	The New Promise of Mitochondrial Transplantation for Myocardial Recovery. <i>JACC Basic To Translational Science</i> , 2019, 4, 889-890.	1.9	1
179	Epigenetics in Cardiac Hypertrophy and Heart Failure. <i>JACC Basic To Translational Science</i> , 2019, 4, 976-993.	1.9	74
180	Impact of chronic dietary red meat, white meat, or non-meat protein on trimethylamine N-oxide metabolism and renal excretion in healthy men and women. <i>European Heart Journal</i> , 2019, 40, 583-594.	1.0	297

#	ARTICLE	IF	CITATIONS
181	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0
182	The use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 137-155.	2.9	605
183	Dietary metabolism, the gut microbiome, and heart failure. <i>Nature Reviews Cardiology</i> , 2019, 16, 137-154.	6.1	449
184	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
185	Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. <i>Acta Cardiologica</i> , 2019, 74, 100-107.	0.3	21
186	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 428-438.	0.7	31
187	Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a perâ€­protocol analysis of CARRESSâ€­HF. <i>European Journal of Heart Failure</i> , 2018, 20, 1148-1156.	2.9	51
188	Palliative Care in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 43.	0.4	8
189	I will take my heart failure â€”lactateâ€”freeâ€” please. <i>European Journal of Heart Failure</i> , 2018, 20, 1019-1020.	2.9	3
190	Correlation of Highâ€­Density Lipoproteinâ€­Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1240-1250.	2.9	19
191	Relative quantification of betaâ€­adrenergic receptor in peripheral blood cells using flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 563-570.	1.1	10
192	Novel Insights and Treatment Strategies for Right Heart Failure. <i>Current Heart Failure Reports</i> , 2018, 15, 141-155.	1.3	9
193	Hemodialysisâ€­induced cardiovascular disease. <i>Seminars in Dialysis</i> , 2018, 31, 258-267.	0.7	97
194	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. <i>Circulation</i> , 2018, 137, 2016-2028.	1.6	239
195	Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low. <i>Acta Cardiologica</i> , 2018, 73, 335-341.	0.3	11
196	Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. <i>International Journal of Cardiology</i> , 2018, 252, 112-116.	0.8	12
197	Gut microbiota in cardiovascular disease and heart failure. <i>Clinical Science</i> , 2018, 132, 85-91.	1.8	63
198	Meta-Analysis Comparing Frequency of Overweight Versus Normal Weight in Patients With New-Onset Heart Failure. <i>American Journal of Cardiology</i> , 2018, 121, 836-843.	0.7	4

#	ARTICLE	IF	CITATIONS
199	Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	5
200	Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2018, 38, 193-205.	0.6	40
201	Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology. <i>Heart Rhythm</i> , 2018, 15, 130-136.	0.3	15
202	Diuretics in cardiorenal syndrome: what's new?. <i>Intensive Care Medicine</i> , 2018, 44, 359-362.	3.9	4
203	Inflammation and cardio-renal interactions in heart failure: a potential role for interleukin-6. <i>European Journal of Heart Failure</i> , 2018, 20, 933-934.	2.9	24
204	Metabolic Biomarkers in Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 109-118.	1.0	44
205	Protecting the heart in cancer therapy. <i>F1000Research</i> , 2018, 7, 1566.	0.8	17
206	Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 180.	1.1	2
207	Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. <i>JCI Insight</i> , 2018, 3, .	2.3	122
208	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	3.8	187
209	Impact of Individual Traits, Saturated Fat, and Protein Source on the Gut Microbiome. <i>MBio</i> , 2018, 9, .	1.8	70
210	Big data, artificial intelligence, and cardiovascular precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 305-317.	0.4	18
211	The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients. <i>Archives of Medical Science</i> , 2018, 14, 1003-1009.	0.4	9
212	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
213	Can Blood Volume Analysis-Guided Acute Heart Failure Therapy Improve Clinical Outcomes?. <i>JACC: Heart Failure</i> , 2018, 6, 949-950.	1.9	3
214	Effect of Cardiac Resynchronization Therapy on Exercise-Induced Pulmonary Hypertension and Right Ventricular-Arterial Coupling. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007813.	1.3	26
215	Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009664.	1.6	16
216	Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2040-2050.	1.2	209

#	ARTICLE	IF	CITATIONS
217	Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential. <i>Circulation Research</i> , 2018, 123, 1164-1176.	2.0	122
218	Telocinobufagin, a Novel Cardiotoxic Steroid, Promotes Renal Fibrosis via Na ⁺ /K ⁺ -ATPase Profibrotic Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2566.	1.8	21
219	Intensive Blood Pressure Control and Body Size. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1317-1318.	1.2	2
220	Serum Chloride Levels Track With Survival in Patients With Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 541-549.	0.4	24
221	Driving with the headlights on: Measuring adequate urinary sodium excretion on the road to precision diuresis. <i>American Heart Journal</i> , 2018, 203, 93-94.	1.2	0
222	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. <i>Current Hypertension Reports</i> , 2018, 20, 75.	1.5	62
223	Genetic, dietary, and sex-specific regulation of hepatic ceramides and the relationship between hepatic ceramides and IR [S]. <i>Journal of Lipid Research</i> , 2018, 59, 1164-1174.	2.0	26
224	Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT. <i>European Journal of Heart Failure</i> , 2018, 20, 1436-1443.	2.9	31
225	Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. <i>Progress in Transplantation</i> , 2018, 28, 220-225.	0.4	10
226	Dermal Interstitial Alterations in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e004763.	1.6	15
227	Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 123.	1.6	42
228	Impact of early treatment with intravenous vasodilators and blood pressure reduction in acute heart failure. <i>Open Heart</i> , 2018, 5, e000845.	0.9	13
229	Paraoxonase 2 prevents the development of heart failure. <i>Free Radical Biology and Medicine</i> , 2018, 121, 117-126.	1.3	21
230	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
231	Genetic Reduction in Left Ventricular Protein Kinase C- β and Adverse Ventricular Remodeling in Human Subjects. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001901.	1.6	10
232	L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. <i>Journal of Clinical Investigation</i> , 2018, 129, 373-387.	3.9	216
233	A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality. <i>Journal of Clinical Investigation</i> , 2018, 128, 1154-1163.	3.9	34
234	Global myocardial oedema in advanced decompensated heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 787-794.	0.5	50

#	ARTICLE	IF	CITATIONS
235	Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1014-1022.	2.9	80
236	Impact of Ultrafiltration on Serum Sodium Homeostasis and its Clinical Implication in Patients With Acute Heart Failure, Congestion, and Worsening Renal Function. <i>Circulation: Heart Failure</i> , 2017, 10, e003603.	1.6	11
237	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	1.0	317
238	Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. <i>International Journal of Cardiology</i> , 2017, 232, 12-23.	0.8	64
239	Advances in new therapeutic targets for atherosclerosis. <i>Nature Reviews Cardiology</i> , 2017, 14, 71-72.	6.1	12
240	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. <i>Current Heart Failure Reports</i> , 2017, 14, 106-116.	1.3	16
241	Alternative Biomarkers for Combined Biology. <i>Heart Failure Clinics</i> , 2017, 13, 381-401.	1.0	2
242	Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β_1 -Adrenergic Receptors. <i>Journal of the American College of Cardiology</i> , 2017, 69, 968-977.	1.2	28
243	Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications. <i>Current Heart Failure Reports</i> , 2017, 14, 117-126.	1.3	66
244	B-type natriuretic peptide and echocardiography reflect volume changes during pregnancy. <i>Journal of Perinatal Medicine</i> , 2017, 45, 577-583.	0.6	35
245	Left Ventricular Size does not Modify the Effect of QRS Duration in Predicting Response to Cardiac Resynchronization Therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 482-487.	0.5	10
246	Amyloid heart disease: genetics translated into disease-modifying therapy. <i>Heart</i> , 2017, 103, 812-817.	1.2	20
247	High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 748-755.	2.9	27
248	Echocardiographic Predictors of Long-Term Survival in Patients Undergoing Cardiac Resynchronization Therapy: What Is the Optimal Metric?. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 410-415.	0.8	19
249	Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 287-296.	1.9	104
250	Relation of Red Cell Distribution Width to Left Ventricular End-Diastolic Pressure and Mortality in Patients With and Without Heart Failure. <i>American Journal of Cardiology</i> , 2017, 119, 1421-1427.	0.7	13
251	Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects. <i>Circulation</i> , 2017, 135, 1671-1673.	1.6	206
252	Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling. <i>Circulation Research</i> , 2017, 121, 56-70.	2.0	59

#	ARTICLE	IF	CITATIONS
253	Renal response to intravascular volume expansion in euvoletic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications. <i>International Journal of Cardiology</i> , 2017, 243, 318-325.	0.8	5
254	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1958.	3.8	329
255	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2428-2445.	1.2	88
256	Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 6</i>	0.7	13
257	The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue. <i>Cell Reports</i> , 2017, 19, 2451-2461.	2.9	194
258	The Role and Impact of Gut Microbiota in Cardiovascular Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 799-800.	0.4	11
259	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
260	Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval. <i>JACC: Heart Failure</i> , 2017, 5, 460-463.	1.9	12
261	Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated ^{18}F -Fluoro-2-deoxyglucose Positron Emission Tomography. <i>Pulmonary Circulation</i> , 2017, 7, 428-438.	0.8	34
262	Navigating air travel and cardiovascular concerns: Is the sky the limit?. <i>Clinical Cardiology</i> , 2017, 40, 660-666.	0.7	16
263	Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. <i>Clinical Biochemistry</i> , 2017, 50, 491-495.	0.8	34
264	Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. <i>European Heart Journal</i> , 2017, 38, 1872-1882.	1.0	126
265	An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial. <i>International Journal of Cardiology</i> , 2017, 241, 277-282.	0.8	27
266	Gut Microbiota in Cardiovascular Health and Disease. <i>Circulation Research</i> , 2017, 120, 1183-1196.	2.0	1,079
267	The Gut Microbiome and Its Role in Cardiovascular Diseases. <i>Circulation</i> , 2017, 135, 1008-1010.	1.6	113
268	Lamin A/C Cardiomyopathies: Current Understanding and Novel Treatment Strategies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 21.	0.4	23
269	Targeting the Microbiome in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 27.	0.4	40
270	Predicting long-term prognosis in stable peripheral artery disease with baseline functional capacity estimated by the Duke Activity Status Index. <i>American Heart Journal</i> , 2017, 184, 17-25.	1.2	8

#	ARTICLE	IF	CITATIONS
271	Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus. <i>Clinical Chemistry</i> , 2017, 63, 297-306.	1.5	181
272	Reconsidering Renal Sympathetic Denervation for Heart Failure. <i>JACC Basic To Translational Science</i> , 2017, 2, 282-284.	1.9	1
273	Effect of PR interval prolongation on long-term outcomes in patients with left bundle branch block vs nonâ€“left bundle branch block morphologies undergoing cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2017, 14, 1523-1528.	0.3	17
274	Impacto de la microbiota intestinal en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 799-800.	0.6	15
275	Compensatory Distal Reabsorption Drives Diuretic Resistance in Human Heart Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3414-3424.	3.0	75
276	Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation. <i>Hypertension</i> , 2017, 70, 479-485.	1.3	53
277	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 70, 809.	1.2	2
278	Gut microbiome and its role in cardiovascular diseases. <i>Current Opinion in Cardiology</i> , 2017, 32, 761-766.	0.8	139
279	Intrarenal Flow Alterations During Transition From Euvolemia to Intravascular Volume Expansion in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 672-681.	1.9	98
280	Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 823-832.	1.9	63
281	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	3.0	199
282	Peripheral Venous Pressure Measurements in Patients With Acute Decompensated Heart Failure (PVP-HF). <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	16
283	Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 152-162.	1.2	87
284	Therapeutic Strategies Targeting Inherited Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2017, 14, 321-330.	1.3	16
285	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). <i>American Journal of Cardiology</i> , 2017, 119, 78-83.	0.7	44
286	Plasma Volume Is Normal but Heterogeneously Distributed, and True Anemia Is Highly Prevalent in Patients With Stable Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 138-144.	0.7	17
287	Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. <i>American Heart Journal</i> , 2017, 183, 35-39.	1.2	5
288	Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2017, 119, 65-70.	0.7	34

#	ARTICLE	IF	CITATIONS
289	Microbiome, trimethylamine N-oxide, and cardiometabolic disease. <i>Translational Research</i> , 2017, 179, 108-115.	2.2	105
290	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
291	Gut Microbiota and Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2017, 19, 39.	2.0	62
292	Dissociation of Objective and Subjective Daytime Sleepiness and Biomarkers of Systemic Inflammation in Sleep-Disordered Breathing and Systolic Heart Failure. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 1411-1422.	1.4	39
293	Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2017, 18, 147032031772991.	1.0	19
294	Discordance between 'actual' and 'scheduled' check-in times at a heart failure clinic. <i>PLoS ONE</i> , 2017, 12, e0187849.	1.1	10
295	Recent Advances in Understanding and Managing Cardiomyopathy. <i>F1000Research</i> , 2017, 6, 1659.	0.8	2
296	PVDOMICS. <i>Circulation Research</i> , 2017, 121, 1136-1139.	2.0	113
297	Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. <i>JCI Insight</i> , 2017, 2, .	2.3	69
298	Cardiogenic shock: From ECMO to Impella and beyond. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 287-295.	0.6	21
299	Gut microbial function and bacterially derived signals in cardiovascular disease. <i>Biochemist</i> , 2017, 39, 22-25.	0.2	0
300	Abstract 21098: Variables From the CMS Heart Failure Readmission Model Poorly Predict 30-Day Rehospitalization Risk in Heart Failure Patients From a Large Academic Hospital System. <i>Circulation</i> , 2017, 136, .	1.6	0
301	The rs11515 Polymorphism Is More Frequent and Associated With Aggressive Breast Tumors with Increased ANRIL and Decreased p16INK4a Expression. <i>Frontiers in Oncology</i> , 2016, 5, 306.	1.3	33
302	Intrarenal Venous Flow. <i>JACC: Heart Failure</i> , 2016, 4, 683-686.	1.9	79
303	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
304	Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45
305	Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 753-760.	0.7	141
306	Dietary metabolism, gut microbiota and acute heart failure. <i>Heart</i> , 2016, 102, 813-814.	1.2	13

#	ARTICLE	IF	CITATIONS
307	Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2016, 5, .	1.6	133
308	Reply. Journal of the American College of Cardiology, 2016, 68, 2917-2918.	1.2	3
309	Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden. Journal of the American College of Cardiology, 2016, 67, 2620-2628.	1.2	186
310	Heart Failure and Inflammatory Arthritis: the Relationship of Systemic Inflammation. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	0
311	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. International Journal of Cardiology, 2016, 218, 136-143.	0.8	8
312	Pathophysiologic Insights into Heart Rate Reduction in Heart Failure: Implications in the Use of Beta-Blockers and Ivabradine. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 13.	0.4	6
313	Autoantibodies Specifically Against β_1 Adrenergic Receptors and Adverse Clinical Outcome in Patients With Chronic Systolic Heart Failure in the β_2 -Blocker Era: The Importance of Immunoglobulin G3 Subclass. Journal of Cardiac Failure, 2016, 22, 417-422.	0.7	20
314	Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. Circulation: Heart Failure, 2016, 9, e002115.	1.6	34
315	Reduced Cardiac Index Is Not the Dominant Driver of Renal Dysfunction in Heart Failure. Journal of the American College of Cardiology, 2016, 67, 2199-2208.	1.2	98
316	¿Cuál debe ser el objetivo en la insuficiencia cardiaca: la hemoglobina o el hierro?. Revista Espanola De Cardiologia, 2016, 69, 811-812.	0.6	0
317	Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. Molecular Genetics and Metabolism, 2016, 119, 187-206.	0.5	41
318	Carbamylated Low-Density Lipoprotein and Thrombotic Risk in Chronic Kidney Disease. Journal of the American College of Cardiology, 2016, 68, 1677-1679.	1.2	3
319	Ambient Air Pollution Is Associated With the Severity of Coronary Atherosclerosis and Incident Myocardial Infarction in Patients Undergoing Elective Cardiac Evaluation. Journal of the American Heart Association, 2016, 5, .	1.6	51
320	What Should We Target in Heart Failure: Hemoglobin or Iron?. Revista Espanola De Cardiologia (English Ed), 2016, 69, 811-812.	0.4	0
321	Focal fibrosis and diffuse fibrosis are predictors of reversed left ventricular remodeling in patients with non-ischemic cardiomyopathy. International Journal of Cardiology, 2016, 221, 498-504.	0.8	19
322	Rationale and Design of the ATHENA-HF Trial. JACC: Heart Failure, 2016, 4, 726-735.	1.9	30
323	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 2016, 18, 290-297.	2.9	47
324	Practical Pharmacogenomic Approaches to Heart Failure Therapeutics. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 60.	0.4	7

#	ARTICLE	IF	CITATIONS
325	Hypochloremia and Diuretic Resistance in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	102
326	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	46
327	Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing. <i>Endocrinology</i> , 2016, 157, 4865-4874.	1.4	14
328	Genetic Predispositions to Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	0.8	0
329	Endothelinâ€1 is independently associated with 180â€day mortality after adjusting for body mass index. <i>European Journal of Heart Failure</i> , 2016, 18, 876-876.	2.9	1
330	The Impact of Donor and Recipient Renal Dysfunction on Cardiac Allograft Survival: Insights Into Reno-Cardiac Interactions. <i>Journal of Cardiac Failure</i> , 2016, 22, 368-375.	0.7	11
331	Intestinal Microbiotaâ€Generated Metabolite Trimethylamineâ€Nâ€oxide and 5â€Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGEâ€Like Patient Cohort. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	198
332	Hypochloreaemia is strongly and independently associated with mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 660-668.	2.9	94
333	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002453.	1.6	61
334	Assessing Impedance in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002761.	1.6	1
335	Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002333.	1.6	25
336	Prognostic Value of Baseline and Changesâin Circulating Soluble ST2 Levelsâand the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	1.9	45
337	Management of Cardio-Renal Syndrome and Diuretic Resistance. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2016, 18, 11.	0.4	37
338	A Test in Context. <i>Journal of the American College of Cardiology</i> , 2016, 67, 330-337.	1.2	56
339	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2016, 117, 404-411.	0.7	47
340	We Are Not Alone. <i>JACC: Heart Failure</i> , 2016, 4, 228-229.	1.9	4
341	Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1299-1304.	0.7	10
342	Transient Hyponatremia During Hospitalization for Acute Heart Failure. <i>American Journal of Medicine</i> , 2016, 129, 620-627.	0.6	19

#	ARTICLE	IF	CITATIONS
343	Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. <i>Journal of Cardiac Failure</i> , 2016, 22, 884-890.	0.7	35
344	Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. <i>Nature Communications</i> , 2016, 7, 10558.	5.8	108
345	Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. <i>Cell</i> , 2016, 165, 111-124.	13.5	1,358
346	Exploring the Microbiome in Heart Failure. <i>Current Heart Failure Reports</i> , 2016, 13, 103-109.	1.3	67
347	Novel Biomarkers of Heart Failure: Do They Have Incremental Clinical Utility?. <i>Journal of Cardiac Failure</i> , 2016, 22, 263-264.	0.7	0
348	Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002370.	1.6	109
349	Choline Diet and Its Gut Microbeâ€œDerived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overloadâ€œInduced Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002314.	1.6	265
350	Trimethylamine N-Oxide as a Novel Therapeutic Target in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 8-10.	3.0	12
351	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32.	0.7	48
352	Probiotic therapy to attenuate weight gain and trimethylamineâ€œN</i></i>â€œOxide generation: A cautionary tale. <i>Obesity</i> , 2015, 23, 2321-2322.	1.5	6
353	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. <i>Acta Cardiologica</i> , 2015, 70, 265-273.	0.3	71
354	Response and tolerance to oral vasodilator upâ€œtitration after intravenous vasodilator therapy in advanced decompensated heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 956-963.	2.9	6
355	Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 689-696.	2.9	35
356	Recent advances in treatment of heart failure. <i>F1000Research</i> , 2015, 4, 1475.	0.8	11
357	Protein carbamylation and cardiovascular disease. <i>Kidney International</i> , 2015, 88, 474-478.	2.6	94
358	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2618-2629.	1.2	26
359	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2683-2684.	1.2	0
360	Genetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 545-553.	1.1	4

#	ARTICLE	IF	CITATIONS
361	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
362	Renin-Angiotensin-Aldosterone System Activation During Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 108-111.	1.9	25
363	Intestinal Microbiota-Dependent Phosphatidylcholine Metabolites, Diastolic Dysfunction, and Adverse Clinical Outcomes in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 91-96.	0.7	271
364	Renal Failure Requiring Dialysis Complicating Slow Continuous Ultrafiltration in Acute Heart Failure: Importance of Systolic Perfusion Pressure. <i>Journal of Cardiac Failure</i> , 2015, 21, 108-115.	0.7	9
365	Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. <i>Heart Rhythm</i> , 2015, 12, 517-523.	0.3	20
366	The Pathophysiological Role of Interstitial Sodium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 378-388.	1.2	125
367	Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated Heart Failure Treatment. <i>American Journal of Medicine</i> , 2015, 128, 776-783.e4.	0.6	88
368	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
369	Hyponatremia in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 480-492.	1.2	124
370	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2015, 115, 918-923.	0.7	4
371	Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. <i>European Journal of Heart Failure</i> , 2015, 17, 320-328.	2.9	18
372	Prognostic Comparison of Different Sensitivity Cardiac Troponin Assays in Stable Heart Failure. <i>American Journal of Medicine</i> , 2015, 128, 276-282.	0.6	37
373	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	7
374	Long-term dietary habits and interventions in solid-organ transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1357-1365.	0.3	18
375	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 66, 659-666.	1.2	123
376	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
377	Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 390-394.	0.3	14
378	Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis. <i>Current Diabetes Reports</i> , 2015, 15, 63.	1.7	23

#	ARTICLE	IF	CITATIONS
379	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 66, 96-97.	1.2	4
380	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
381	Utilizing Cardiac Biomarkers to Detect and Prevent Chemotherapy-Induced Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2015, 12, 255-262.	1.3	20
382	Prevention of Heart Failure in Patients with Chronic Kidney Disease. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	1
383	Diuretic response in acute heart failure—analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
384	Worsening Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 404-407.	1.9	3
385	Can We Save the Kidneys by Protecting the Heart?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 165-166.	2.2	1
386	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. <i>American Heart Journal</i> , 2015, 169, 806-812.	1.2	44
387	Contribution of Environmental Toxins in the Pathogenesis of Idiopathic Cardiomyopathies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 381.	0.4	2
388	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
389	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. <i>Nature Genetics</i> , 2015, 47, 1282-1293.	9.4	294
390	MetaDiff: differential isoform expression analysis using random-effects meta-regression. <i>BMC Bioinformatics</i> , 2015, 16, 208.	1.2	9
391	Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2015, 373, 2314-2324.	13.9	453
392	Reverse Remodeling and Prognosis Following Kidney Transplantation in Contemporary Patients With Cardiac Dysfunction. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1779-1787.	1.2	66
393	Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. <i>Journal of Cardiac Failure</i> , 2015, 21, 973-980.	0.7	179
394	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
395	Evolving Approaches to Genetic Evaluation of Specific Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2015, 12, 339-349.	1.3	12
396	Comparative Efficacy of Cardiac Resynchronization Therapy in Africans Americans Compared With European Americans. <i>American Journal of Cardiology</i> , 2015, 116, 1101-1105.	0.7	2

#	ARTICLE	IF	CITATIONS
397	Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrate Stress in Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 1068-1076.	1.6	48
398	RNA-Seq identifies novel myocardial gene expression signatures of heart failure. <i>Genomics</i> , 2015, 105, 83-89.	1.3	220
399	Prognostic Value of Estimating Functional Capacity With the Use of the Duke Activity Status Index in Stable Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 44-50.	0.7	41
400	Long-Term Outcomes in Patients With Ambulatory New York Heart Association Class III and IV Heart Failure Undergoing Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 82-85.	0.7	15
401	Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 57-61.	0.7	111
402	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. <i>Nature</i> , 2015, 518, 102-106.	13.7	581
403	Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease. <i>Circulation Research</i> , 2015, 116, 448-455.	2.0	898
404	Biomarkers: Their potential in the diagnosis and treatment of heart failure. <i>Cleveland Clinic Journal of Medicine</i> , 2015, 82, S28-S35.	0.6	25
405	Abstract 18178: Cardiotonic Steroid Lactone Ring Hydrolysis by Paraoxonases Attenuates Na/K ATPase Mediated Signaling. <i>Circulation</i> , 2015, 132, .	1.6	0
406	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
407	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
408	The kidney in congestive heart failure: are natriuresis, sodium, and diuretics really the good, the bad and the ugly? <i>European Journal of Heart Failure</i> , 2014, 16, 133-142.	2.9	125
409	Natriuretic Peptide Testing in High-Risk Pregnancy: A Preventive Opportunity?. <i>Current Heart Failure Reports</i> , 2014, 11, 471-476.	1.3	6
410	The contributory role of gut microbiota in cardiovascular disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4204-4211.	3.9	519
411	Plasma Ceruloplasmin, a Regulator of Nitric Oxide Activity, and Incident Cardiovascular Risk in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 462-467.	2.2	18
412	Coenzyme Q supplementation in pulmonary arterial hypertension. <i>Redox Biology</i> , 2014, 2, 884-891.	3.9	26
413	Prognostic Value of Elevated Serum Ceruloplasmin Levels in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 946-952.	0.7	38
414	A Combined-Biomarker Approach to Clinical Phenotyping Renal Dysfunction in Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 912-919.	0.7	46

#	ARTICLE	IF	CITATIONS
415	Site-specific Nitration of Apolipoprotein A-I at Tyrosine 166 Is Both Abundant within Human Atherosclerotic Plaque and Dysfunctional. <i>Journal of Biological Chemistry</i> , 2014, 289, 10276-10292.	1.6	84
416	A Clinical Prediction Rule to Identify Patients at Heightened Risk for Early Demise Following Cardiac Resynchronization Therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 278-282.	0.8	5
417	Autoantibodies and Cardiovascular Dysfunction: Cause or Consequence?. <i>Current Heart Failure Reports</i> , 2014, 11, 500-508.	1.3	17
418	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. <i>Journal of the American Heart Association</i> , 2014, 3, e000960.	1.6	29
419	Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 766-772.	1.6	71
420	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
421	Usefulness of Elevated Urine Neopterin Levels in Assessing Cardiac Dysfunction and Exercise Ventilation Inefficiency in Patients With Chronic Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 113, 1839-1843.	0.7	9
422	Influence of Age-Related Versus Non-Related Age-Related Renal Dysfunction on Survival in Patients With Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2014, 113, 127-131.	0.7	7
423	Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency. <i>Journal of the American College of Cardiology</i> , 2014, 63, 853-871.	1.2	102
424	Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: State of the art review and focus on emerging nuclear techniques. <i>Journal of Nuclear Cardiology</i> , 2014, 21, 271-283.	1.4	103
425	Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure. <i>Current Heart Failure Reports</i> , 2014, 11, 58-63.	1.3	95
426	Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases. <i>Heart Failure Reviews</i> , 2014, 19, 295-304.	1.7	4
427	Double-Chambered Right Ventricle and Bicuspid Pulmonic Valve. <i>Journal of the American College of Cardiology</i> , 2014, 63, 569.	1.2	0
428	Loop Diuretic Efficiency. <i>Circulation: Heart Failure</i> , 2014, 7, 261-270.	1.6	209
429	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated With Poor Long-Term Outcomes in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 392-399.	0.7	120
430	Increased Need for Right Ventricular Support in Patients With Chemotherapy-Induced Cardiomyopathy Undergoing Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , 2014, 63, 240-248.	1.2	99
431	An abundant dysfunctional apolipoprotein A1 in human atheroma. <i>Nature Medicine</i> , 2014, 20, 193-203.	15.2	316
432	Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. <i>European Heart Journal</i> , 2014, 35, 904-910.	1.0	463

#	ARTICLE	IF	CITATIONS
433	Prognostic Value of Elevated Levels of Intestinal Microbe-Generated Metabolite Trimethylamine-N-Oxide in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1908-1914.	1.2	533
434	Prognostic Significance of Left Atrial Appendage "Sludge" in Patients with Atrial Fibrillation: A New Transesophageal Echocardiographic Thromboembolic Risk Factor. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 1176-1183.	1.2	62
435	β -Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L-Carnitine to TMAO. <i>Cell Metabolism</i> , 2014, 20, 799-812.	7.2	416
436	Prognostic Value of Glomerular Filtration Changes Versus Natriuretic Response in Decompensated Heart Failure With Reduced Ejection. <i>Journal of Cardiac Failure</i> , 2014, 20, 817-824.	0.7	17
437	Terminology and definition of changes renal function in heart failure. <i>European Heart Journal</i> , 2014, 35, 3413-3416.	1.0	108
438	Comparative Genome-Wide Association Studies in Mice and Humans for Trimethylamine <i>N</i> -Oxide, a Proatherogenic Metabolite of Choline and <i>L</i> -Carnitine. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1307-1313.	1.1	119
439	S100A1 in Human Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 612-618.	1.6	9
440	Precision of Echocardiographic Estimates of Right Atrial Pressure in Patients with Acute Decompensated Heart Failure. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 1072-1078.e2.	1.2	37
441	Insufficient Natriuretic Response to Continuous Intravenous Furosemide Is Associated with Poor Long-Term Outcomes in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, S40-S41.	0.7	2
442	Genetic and Nongenetic Factors Influencing Pharmacokinetics of B-Type Natriuretic Peptide. <i>Journal of Cardiac Failure</i> , 2014, 20, 662-668.	0.7	13
443	Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients. <i>American Journal of Cardiology</i> , 2014, 113, 1893-1898.	0.7	33
444	Heart Failure Notwithstanding Ejection Fraction (HF _{NEF})—A Possible Unifying Hypothesis?. <i>Journal of Cardiac Failure</i> , 2014, 20, 60-62.	0.7	3
445	Right Ventricular Global Longitudinal Strain Provides Prognostic Value Incremental to Left Ventricular Ejection Fraction in Patients with Heart Failure. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 726-732.	1.2	93
446	Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: Fate of "nonresponders". <i>Heart Rhythm</i> , 2014, 11, 412-416.	0.3	45
447	Utilization Pattern of Mineralocorticoid Receptor Antagonists in Contemporary Patients Hospitalized With Acute Decompensated Heart Failure: A Single-Center Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, 229-235.	0.7	19
448	Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 318-320.	0.3	29
449	Contemporary Insights and Novel Treatment Approaches to Central Sleep Apnea Syndrome in Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 322.	0.4	7
450	Outcomes of Infected Cardiovascular Implantable Devices in Dialysis Patients. <i>American Journal of Nephrology</i> , 2014, 40, 280-287.	1.4	21

#	ARTICLE	IF	CITATIONS
451	Dexamethasone, Light Anaesthesia, and Tight Glucose Control (DeLiT) Randomized Controlled Trial. <i>Survey of Anesthesiology</i> , 2014, 58, 37-39.	0.1	0
452	Abstract 17746: Telecinobufagin, a Novel Cardiotonic Steroid, Promotes Myocardial and Renal Fibrosis via Na/K-ATPase Profibrotic Signalling Pathways. <i>Circulation</i> , 2014, 130, .	1.6	2
453	Recent advances in hypertrophic cardiomyopathy. <i>F1000prime Reports</i> , 2014, 6, 12.	5.9	6
454	Targeting Oxidative Stress in Heart Failure. , 2014, , 993-1019.		0
455	miRNA-548c: A specific signature in circulating PBMCs from dilated cardiomyopathy patients. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 62, 131-141.	0.9	48
456	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1495-1539.	1.2	276
457	Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension. <i>Respiratory Research</i> , 2013, 14, 6.	1.4	42
458	Abdominal Contributions to Cardiorenal Dysfunction in Congestive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 485-495.	1.2	322
459	Pharmacologic Management of Chronic Reno-Cardiac Syndrome. <i>Current Heart Failure Reports</i> , 2013, 10, 54-62.	1.3	14
460	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1659.	1.2	0
461	A Randomized Controlled Pilot Study of Outcomes of Strict Allowance of Fluid Therapy in Hyponatremic Heart Failure (SALT-HF). <i>Journal of Cardiac Failure</i> , 2013, 19, 1-9.	0.7	56
462	Survival of Patients With Biventricular Devices After Device Infection, Extraction, and Reimplantation. <i>JACC: Heart Failure</i> , 2013, 1, 508-513.	1.9	21
463	Single Exhaled Breath Metabolomic Analysis Identifies Unique Breathprint in Patients With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1463-1464.	1.2	68
464	Efficacy of the CHADS2 Scoring System to Assess Left Atrial Thrombogenic Milieu Risk Before Cardioversion of Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2013, 112, 678-683.	0.7	29
465	Increasing Serum Soluble Angiotensin-Converting Enzyme 2 Activity After Intensive Medical Therapy Is Associated With Better Prognosis in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 605-610.	0.7	25
466	Potential Effects of Digoxin on Long-Term Renal and Clinical Outcomes in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 295-302.	0.7	22
467	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Circulation</i> , 2013, 128, e240-327.	1.6	2,335
468	Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy. <i>Europace</i> , 2013, 15, 1747-1756.	0.7	21

#	ARTICLE	IF	CITATIONS
469	Right Ventricular Afterload and the Role of Nitric Oxide Metabolism in Left-Sided Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 712-721.	0.7	19
470	Aspirin Hydrolysis in Plasma Is a Variable Function of Butyrylcholinesterase and Platelet-activating Factor Acetylhydrolase 1b2 (PAFAH1b2). <i>Journal of Biological Chemistry</i> , 2013, 288, 11940-11948.	1.6	34
471	Novel Urinary Biomarkers in Detecting Acute Kidney Injury, Persistent Renal Impairment, and All-Cause Mortality Following Decongestive Therapy in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 621-628.	0.7	67
472	Myeloperoxidase in Cardiovascular Disease. <i>Advances in Clinical Chemistry</i> , 2013, 62, 1-32.	1.8	23
473	Timing of Hemoconcentration During Treatment of Acute Decompensated Heart Failure and Subsequent Survival. <i>Journal of the American College of Cardiology</i> , 2013, 62, 516-524.	1.2	148
474	Function and Distribution of Apolipoprotein A1 in the Artery Wall Are Markedly Distinct From Those in Plasma. <i>Circulation</i> , 2013, 128, 1644-1655.	1.6	98
475	Treatment Strategies for the Prevention of Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 331-340.	1.3	9
476	Incorporating Common Biomarkers into the Clinical Management of Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 450-457.	1.3	5
477	Prognosis of Morbid Obesity Patients With Advanced Heart Failure. <i>Congestive Heart Failure</i> , 2013, 19, 160-164.	2.0	48
478	Clinical Outcomes After Tricuspid Valve Annuloplasty in Addition to Mitral Valve Surgery. <i>Congestive Heart Failure</i> , 2013, 19, 70-76.	2.0	7
479	Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. <i>Heart</i> , 2013, 99, 681-689.	1.2	68
480	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. <i>Journal of the American College of Cardiology</i> , 2013, 61, 957-970.	1.2	58
481	Uptitration of Renin-Angiotensin System Blocker and Beta-Blocker Therapy in Patients Hospitalized for Heart Failure With Reduced Versus Preserved Left Ventricular Ejection Fractions. <i>American Journal of Cardiology</i> , 2013, 112, 1913-1920.	0.7	23
482	QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2013, 10, 55-60.	0.3	43
483	Protein Carbamylation in Chronic Systolic Heart Failure: Relationship With Renal Impairment and Adverse Long-Term Outcomes. <i>Journal of Cardiac Failure</i> , 2013, 19, 219-224.	0.7	30
484	Impact of Left Ventricular Diastolic Function on Left Atrial Mechanics in Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2013, 112, 821-826.	0.7	13
485	Usefulness of Cardiac Biomarker Score for Risk Stratification in Stable Patients Undergoing Elective Cardiac Evaluation Across Glycemic Status. <i>American Journal of Cardiology</i> , 2013, 111, 465-470.	0.7	15
486	Cardiotonic Modulation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1073-1074.	1.2	46

#	ARTICLE	IF	CITATIONS
487	Biomarkers of Acute Kidney Injury in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 425-426.	1.9	6
488	Nitric oxide bioavailability and adiponectin production in chronic systolic heart failure: relation to severity of cardiac dysfunction. <i>Translational Research</i> , 2013, 162, 26-33.	2.2	9
489	Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk. <i>New England Journal of Medicine</i> , 2013, 368, 1575-1584.	13.9	2,537
490	Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. <i>Nature Medicine</i> , 2013, 19, 576-585.	15.2	3,355
491	2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, e147-e239.	1.2	7,017
492	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	0.7	53
493	Diminished Global Arginine Bioavailability as a Metabolic Defect in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 87-93.	0.7	31
494	Cardiac Resynchronization Therapy in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1293-1303.	2.2	29
495	Fasting 2-Deoxy-2-[¹⁸ F]fluoro-D-glucose Positron Emission Tomography to Detect Metabolic Changes in Pulmonary Arterial Hypertension Hearts over 1 Year. <i>Annals of the American Thoracic Society</i> , 2013, 10, 1-9.	1.5	93
496	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
497	Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. <i>British Journal of Anaesthesia</i> , 2013, 111, 209-221.	1.5	57
498	Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2013, 2, e000104-e000104.	1.6	61
499	Detectable Subclinical Myocardial Necrosis Is Associated With Cardiovascular Risk in Stable Patients With Diabetes. <i>Diabetes Care</i> , 2013, 36, 1126-1131.	4.3	10
500	Protein Carbamylation Predicts Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 853-861.	3.0	122
501	Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1696-1705.	1.1	269
502	Cardiorenal Syndrome Revisited. , 2013, , 63-90.		0
503	CD36 and Na/K-ATPase- β 1 Form a Proinflammatory Signaling Loop in Kidney. <i>Hypertension</i> , 2013, 61, 216-224.	1.3	84
504	Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. <i>Heart</i> , 2013, 99, 314-319.	1.2	16

#	ARTICLE	IF	CITATIONS
505	2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary. <i>Circulation</i> , 2013, 128, 1810-1852.	1.6	2,807
506	Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. <i>European Heart Journal</i> , 2013, 34, 2472-2480.	1.0	114
507	Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. <i>European Journal of Heart Failure</i> , 2013, 15, 203-210.	2.9	58
508	Lack of Concordance in Defining Worsening Renal Function by Rise in Creatinine vs Rise in Cystatin C. <i>Congestive Heart Failure</i> , 2013, 19, E17-21.	2.0	11
509	Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. <i>European Journal of Heart Failure</i> , 2013, 15, 433-440.	2.9	89
510	Prognostic Implications of Relative Hypochromia in Ambulatory Patients With Chronic Systolic Heart Failure. <i>Congestive Heart Failure</i> , 2013, 19, 180-185.	2.0	20
511	Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia. <i>Human Molecular Genetics</i> , 2013, 22, 3381-3393.	1.4	22
512	Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study. <i>Circulation: Heart Failure</i> , 2013, 6, 936-943.	1.6	46
513	Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2013, 2, .	1.6	26
514	Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. <i>Journal of Clinical Investigation</i> , 2013, 123, 3815-3828.	3.9	226
515	Telemonitoring and Sensor Technologies in Chronic Heart Failure. , 2013, , 205-237.		0
516	Abstract 19: Prognostic Value of Plasma Choline and Betaine Depend on the Intestinal Microflora-generated Metabolite Trimethylamine N-oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0
517	Impact of Mitral Regurgitation on Reverse Remodeling and Outcome in Patients Undergoing Cardiac Resynchronization Therapy. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 21-26.	1.3	52
518	Mast Cell Number, Phenotype, and Function in Human Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2012, 2, 220-228.	0.8	55
519	Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events. <i>Circulation: Heart Failure</i> , 2012, 5, 602-609.	1.6	67
520	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 594-600.	0.9	53
521	Clinical and Genetic Association of Serum Paraoxonase and Arylesterase Activities With Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2803-2812.	1.1	153
522	Immunoglobulins Against Tyrosine-Nitrated Epitopes in Coronary Artery Disease. <i>Circulation</i> , 2012, 126, 2392-2401.	1.6	45

#	ARTICLE	IF	CITATIONS
523	Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 597-604.	2.9	76
524	Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. <i>Heart</i> , 2012, 98, 1778-1786.	1.2	77
525	Association of a Genetic Risk Score With Prevalent and Incident Myocardial Infarction in Subjects Undergoing Coronary Angiography. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 441-449.	5.1	40
526	Targeting Endogenous Antioxidants to Prevent Cardiovascular Diseases. <i>Journal of the American Heart Association</i> , 2012, 1, e005215.	1.6	0
527	Prognostic Role of Pulmonary Arterial Capacitance in Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 778-785.	1.6	122
528	Threshold crossing of device-based intrathoracic impedance trends identifies relatively increased mortality risk. <i>European Heart Journal</i> , 2012, 33, 2189-2196.	1.0	33
529	QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. <i>Heart Rhythm</i> , 2012, 9, 1674-1678.	0.3	27
530	Incremental Prognostic Value of Assessing Left Ventricular Myocardial Mechanics in Patients With Chronic Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2074-2081.	1.2	131
531	Management of Comorbid Conditions in Heart Failure. <i>Medical Clinics of North America</i> , 2012, 96, 975-985.	1.1	12
532	Multispecialty approach: The need for heart failure disease management for refining cardiac resynchronization therapy. <i>Heart Rhythm</i> , 2012, 9, S45-S50.	0.3	7
533	Cardiorenal Outcomes After Slow Continuous Ultrafiltration Therapy in Refractory Patients With Advanced Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1906-1912.	1.2	76
534	Troponin I in acute decompensated heart failure: insights from the ASCENDâ€HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
535	Seventy-five genetic loci influencing the human red blood cell. <i>Nature</i> , 2012, 492, 369-375.	13.7	320
536	Reconsidering Ultrafiltration in the Acute Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2351-2352.	13.9	16
537	Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. <i>American Heart Journal</i> , 2012, 163, 156-163.	1.2	108
538	Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 282-287.	0.3	96
539	Progressive Rise in Red Cell Distribution Width Is Associated With Disease Progression in Ambulatory Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2012, 18, 146-152.	0.7	53
540	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93

#	ARTICLE	IF	CITATIONS
541	Design and Performance of a Multisensor Heart Failure Monitoring Algorithm: Results From the Multisensor Monitoring in Congestive Heart Failure (MUSIC) Study. <i>Journal of Cardiac Failure</i> , 2012, 18, 289-295.	0.7	57
542	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	0.7	50
543	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. <i>American Heart Journal</i> , 2012, 164, 616-624.	1.2	45
544	Pulmonary Hypertension Associated With Advanced Systolic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1150-1158.	1.2	56
545	Differential Response to Cardiac Resynchronization Therapy and Clinical Outcomes According to QRS Morphology and QRS Duration. <i>Journal of the American College of Cardiology</i> , 2012, 60, 592-598.	1.2	93
546	Indications for TEE Before Cardioversion for Atrial Fibrillation: Implications for Appropriateness Criteria. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 641-648.	2.3	9
547	Relation of Systemic and Urinary Neutrophil Gelatinase-Associated Lipocalin Levels to Different Aspects of Impaired Renal Function in Patients With Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 1329-1335.	0.7	65
548	H2Sâ€”The Newest Gaseous Messenger on the Block. <i>Journal of Cardiac Failure</i> , 2012, 18, 597-599.	0.7	1
549	Increased Exhaled Nitric Oxide Levels After Exercise in Patients With Chronic Systolic Heart Failure With Pulmonary Venous Hypertension. <i>Journal of Cardiac Failure</i> , 2012, 18, 799-803.	0.7	18
550	Comorbidity Significantly Affects Clinical Outcome After Cardiac Resynchronization Therapy Regardless of Ventricular Remodeling. <i>Journal of Cardiac Failure</i> , 2012, 18, 845-853.	0.7	35
551	Introduction. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 1-2.	1.6	3
552	Translating Metabolomics to Cardiovascular Biomarkers. <i>Progress in Cardiovascular Diseases</i> , 2012, 55, 70-76.	1.6	62
553	Transesophageal Echocardiography and Cardioversion Trends in Patients with Atrial Fibrillation: A 10-Year Survey. <i>Journal of the American Society of Echocardiography</i> , 2012, 25, 962-968.	1.2	7
554	Role of Oxidative Stress in Disease Progression in Stage B, a Pre-cursor of Heart Failure. <i>Heart Failure Clinics</i> , 2012, 8, 101-111.	1.0	20
555	The Chromosome 9p21.3 Coronary Heart Disease Risk Allele Is Associated with Altered Gene Expression in Normal Heart and Vascular Tissues. <i>PLoS ONE</i> , 2012, 7, e39574.	1.1	37
556	A Genome-Wide Association Study for Coronary Artery Disease Identifies a Novel Susceptibility Locus in the Major Histocompatibility Complex. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 217-225.	5.1	125
557	Clinical and Genetic Association of Serum Ceruloplasmin With Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 516-522.	1.1	54
558	Nitrated fibrinogen is a biomarker of oxidative stress in venous thromboembolism. <i>Free Radical Biology and Medicine</i> , 2012, 53, 230-236.	1.3	31

#	ARTICLE	IF	CITATIONS
559	Extracorporeal Ultrafiltration vs Conventional Diuretic Therapy in Advanced Decompensated Heart Failure. <i>Congestive Heart Failure</i> , 2012, 18, 54-63.	2.0	50
560	Association Between Systemic Neutrophil Gelatinase-Associated Lipocalin and Anemia, Relative Hypochromia, and Inflammation in Chronic Systolic Heart Failure. <i>Congestive Heart Failure</i> , 2012, 18, 239-244.	2.0	26
561	Pharmacologic Strategies to Target Oxidative Stress in Heart Failure. <i>Current Heart Failure Reports</i> , 2012, 9, 14-22.	1.3	28
562	The role of aldosterone receptor antagonists in the management of heart failure: An update. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 631-639.	0.6	8
563	The Early Intertwining of the Heart and the Kidney Through an Impaired Natriuretic Response to Acute Volume Expansion. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2104-2105.	1.2	6
564	New gene functions in megakaryopoiesis and platelet formation. <i>Nature</i> , 2011, 480, 201-208.	13.7	401
565	Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2011, 162, 262-267.e3.	1.2	39
566	The impact of left ventricular size on response to cardiac resynchronization therapy. <i>American Heart Journal</i> , 2011, 162, 646-653.	1.2	24
567	Impact of Left Ventricular Remodeling on Diagnostic and Prognostic Value of Tissue Doppler Indices in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 128-134.	0.7	7
568	Antiinflammatory Autoimmune Cellular Responses to Cardiac Troponin I in Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2011, 17, 359-365.	0.7	9
569	Renal Dysfunction Is a Stronger Determinant of Systemic Neutrophil Gelatinase-Associated Lipocalin Levels Than Myocardial Dysfunction in Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 472-478.	0.7	55
570	Improved Algorithm to Detect Fluid Accumulation via Intrathoracic Impedance Monitoring in Heart Failure Patients With Implantable Devices. <i>Journal of Cardiac Failure</i> , 2011, 17, 569-576.	0.7	21
571	Uncovering Interim Clinical Events at the Time of Clinical Encounter by Reviewing Intrathoracic Impedance Threshold Crossings. <i>Journal of Cardiac Failure</i> , 2011, 17, 893-898.	0.7	1
572	Clinical Evaluation of Heart Failure. , 2011, , 511-525.		2
573	Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. <i>Blood</i> , 2011, 117, 3485-3493.	0.6	118
574	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. <i>Nature Genetics</i> , 2011, 43, 333-338.	9.4	1,685
575	Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. <i>Nature</i> , 2011, 472, 57-63.	13.7	4,238
576	Optimizing Cardiac Resynchronization Therapy in Advanced Heart Failure. <i>Congestive Heart Failure</i> , 2011, 17, 147-151.	2.0	10

#	ARTICLE	IF	CITATIONS
577	Integrating Plasma High-Sensitivity C-Reactive Protein and Myeloperoxidase for Risk Prediction in Chronic Systolic Heart Failure. <i>Congestive Heart Failure</i> , 2011, 17, 105-109.	2.0	21
578	Biomarkers in Advanced Heart Failure: Diagnostic and Therapeutic Insights. <i>Congestive Heart Failure</i> , 2011, 17, 169-174.	2.0	13
579	High Levels of Zinc-Protoporphyrin Identify Iron Metabolic Abnormalities in Pulmonary Arterial Hypertension. <i>Clinical and Translational Science</i> , 2011, 4, 253-258.	1.5	24
580	Cellular Proliferative Response to Cardiac Troponin in Patients with Idiopathic Dilated Cardiomyopathy. <i>Clinical and Translational Science</i> , 2011, 4, 317-322.	1.5	3
581	Usefulness of Plasma Galectin-3 Levels in Systolic Heart Failure to Predict Renal Insufficiency and Survival. <i>American Journal of Cardiology</i> , 2011, 108, 385-390.	0.7	169
582	Importance of Adjunctive Heart Failure Optimization Immediately After Implantation to Improve Long-Term Outcomes With Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2011, 108, 409-415.	0.7	55
583	Predictors of Response to Cardiac Resynchronization Therapy in Patients With a Non-Left Bundle Branch Block Morphology. <i>American Journal of Cardiology</i> , 2011, 108, 1576-1580.	0.7	45
584	Device monitoring strategies in acute heart failure syndromes. <i>Heart Failure Reviews</i> , 2011, 16, 491-502.	1.7	16
585	Genetic contribution of the leukotriene pathway to coronary artery disease. <i>Human Genetics</i> , 2011, 129, 617-627.	1.8	42
586	Ivabradine in Heart Failure: To SHIFT or Not to SHIFT. <i>Current Heart Failure Reports</i> , 2011, 8, 1-3.	1.3	2
587	Aldosterone-Receptor Antagonists in Heart Failure: Insights After EMPHASIS-HF. <i>Current Heart Failure Reports</i> , 2011, 8, 7-13.	1.3	22
588	Impact of Systemic Venous Congestion in Heart Failure. <i>Current Heart Failure Reports</i> , 2011, 8, 233-241.	1.3	82
589	Revisiting the cardio-renal hypothesis: the pivotal role of the kidney in congestive heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 820-822.	2.9	4
590	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 180-187.	1.6	319
591	Cardiac Resynchronization Therapy in Patients With Class II Heart Failure and a Wide QRS. <i>Circulation</i> , 2011, 123, 203-208.	1.6	5
592	Risk Prediction with Serial Myeloperoxidase Monitoring in Patients with Acute Chest Pain. <i>Clinical Chemistry</i> , 2011, 57, 1762-1770.	1.5	41
593	Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing Medical Management for Coronary Artery Disease. <i>Clinical Chemistry</i> , 2011, 57, 33-39.	1.5	86
594	Diminished Antioxidant Activity of High-Density Lipoprotein-Associated Proteins in Systolic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 59-64.	1.6	65

#	ARTICLE	IF	CITATIONS
595	Genome-Wide Association Study of Coronary Heart Disease and Its Risk Factors in 8,090 African Americans: The NHLBI CARE Project. <i>PLoS Genetics</i> , 2011, 7, e1001300.	1.5	290
596	The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. <i>Human Genetics</i> , 2010, 127, 101-105.	1.8	13
597	Cardiorenal Syndrome: Diagnosis, Treatment, and Clinical Outcomes. <i>Current Heart Failure Reports</i> , 2010, 7, 167-174.	1.3	15
598	Insights From Internet-Based Remote Intrathoracic Impedance Monitoring as Part of a Heart Failure Disease Management Program. <i>Congestive Heart Failure</i> , 2010, 16, 159-163.	2.0	16
599	Design and Organization of the Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT) Trial: a factorial trial evaluating the effects of corticosteroids, glucose control, and depth-of-anesthesia on perioperative inflammation and morbidity from major non-cardiac surgery. <i>BMC Anesthesiology</i> , 2010, 10, 11.	0.7	24
600	Ventricular Geometry, Strain, and Rotational Mechanics in Pulmonary Hypertension. <i>Circulation</i> , 2010, 121, 259-266.	1.6	216
601	Comprehensive Peroxidase-Based Hematologic Profiling for the Prediction of 1-Year Myocardial Infarction and Death. <i>Circulation</i> , 2010, 122, 70-79.	1.6	17
602	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. <i>Journal of Lipid Research</i> , 2010, 51, 3055-3061.	2.0	76
603	Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac Evaluation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 634-640.	1.1	24
604	Right Ventricular Response to Intensive Medical Therapy in Advanced Decompensated Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 340-346.	1.6	92
605	Improved Prediction of Cardiovascular Disease Based on a Panel of Single Nucleotide Polymorphisms Identified Through Genome-Wide Association Studies. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 468-474.	5.1	88
606	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. <i>Journal of the National Cancer Institute</i> , 2010, 102, 596-604.	3.0	381
607	Cardiorenal syndrome in decompensated heart failure. <i>Heart</i> , 2010, 96, 255-260.	1.2	109
608	Epidemiology of Anemia in Heart Failure. <i>Heart Failure Clinics</i> , 2010, 6, 271-278.	1.0	26
609	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 55, 688-696.	1.2	14
610	Long-Term Reverse Remodeling With Cardiac Resynchronization Therapy. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1788-1795.	1.2	78
611	Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Predicting Worsening Renal Function in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 49-54.	0.7	217
612	Plasma Corin Levels Provide Minimal Prognostic Utility Incremental to Natriuretic Peptides in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 621-627.	0.7	13

#	ARTICLE	IF	CITATIONS
613	Clinical Significance of Endogenous Vasoactive Neurohormones in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 635-640.	0.7	20
614	HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010, 16, e1-e2.	0.7	1,086
615	Statin treatment for patients with heart failure. <i>Nature Reviews Cardiology</i> , 2010, 7, 249-255.	6.1	19
616	Impact of left ventricular volume/mass ratio on diastolic function. <i>European Heart Journal</i> , 2009, 30, 1213-1221.	1.0	31
617	Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. <i>Nature Reviews Cardiology</i> , 2009, 6, 349-355.	6.1	29
618	Biomarkers of risk stratification in congestive heart failure: North American view. <i>Biomarkers in Medicine</i> , 2009, 3, 443-452.	0.6	2
619	Response to Letters Regarding Article, "Tissue Doppler Imaging in the Estimation of Intracardiac Filling Pressure in Decompensated Patients With Advanced Systolic Heart Failure". <i>Circulation</i> , 2009, 120, .	1.6	0
620	Early Cardiac Resynchronization Therapy and Reverse Remodeling in Patients With Mild Heart Failure. <i>Circulation</i> , 2009, 120, 1845-1846.	1.6	6
621	Natriuretic Peptide Measurements in Managing Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 380-381.	1.6	1
622	Targeted Metabolomic Evaluation of Arginine Methylation and Cardiovascular Risks. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1383-1391.	1.1	110
623	Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 1113-1119.	0.7	42
624	Usefulness of Myeloperoxidase Levels in Healthy Elderly Subjects to Predict Risk of Developing Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 1269-1274.	0.7	60
625	Changes in Intrathoracic Impedance are Associated With Subsequent Risk of Hospitalizations for Acute Decompensated Heart Failure: Clinical Utility of Implanted Device Monitoring Without a Patient Alert. <i>Journal of Cardiac Failure</i> , 2009, 15, 475-481.	0.7	102
626	Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2009, 15, 565-571.	0.7	180
627	Measuring impedance in congestive heart failure: Current options and clinical applications. <i>American Heart Journal</i> , 2009, 157, 402-411.	1.2	102
628	Impedance monitoring in heart failure: Are we really measuring hemodynamics?. <i>American Heart Journal</i> , 2009, 158, 152-153.	1.2	6
629	Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 589-596.	1.2	1,313
630	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 600-607.	1.2	65

#	ARTICLE	IF	CITATIONS
631	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. <i>Journal of the American College of Cardiology</i> , 2009, 53, 765-773.	1.2	424
632	Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2061-2067.	1.2	174
633	Role of the CHADS2Score in the Evaluation of Thromboembolic Risk in Patients With Atrial Fibrillation Undergoing Transesophageal Echocardiography Before Pulmonary Vein Isolation. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2032-2039.	1.2	210
634	Right Atrial Volume Index in Chronic Systolic Heart Failure and Prognosis. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 527-534.	2.3	126
635	Enhancing the Prognostic Value of Cardiac Imaging With Multimodal Risk Assessment—Editorials published in <i>JACC: Cardiovascular Imaging</i> reflect the views of the authors and do not necessarily represent the views of <i>JACC: Cardiovascular Imaging</i> or the American College of Cardiology. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 1100-1102.	2.3	0
636	Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 1369-1377.	2.3	221
637	The Metabolic Approach in Patients with Heart Failure: Effects on Left Ventricle Remodeling. <i>Current Pharmaceutical Design</i> , 2009, 15, 850-856.	0.9	6
638	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. <i>Clinical Biochemistry</i> , 2008, 41, 210-221.	0.8	61
639	Usefulness of C-Reactive Protein and Left Ventricular Diastolic Performance for Prognosis in Patients With Left Ventricular Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, 370-373.	0.7	56
640	Prognostic Evaluation of Ambulatory Patients With Advanced Heart Failure. <i>American Journal of Cardiology</i> , 2008, 101, 1297-1302.	0.7	26
641	Gender Differences in Patients Admitted With Advanced Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2008, 102, 454-458.	0.7	23
642	Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 569-576.	1.2	133
643	Elevated Intra-Abdominal Pressure in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 300-306.	1.2	374
644	Sodium Nitroprusside for Advanced Low-Output Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 200-207.	1.2	184
645	Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 750-754.	1.2	231
646	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1671-1678.	1.2	5
647	Future Therapies in Diastolic Heart Failure. , 2008, , 435-441.		0
648	Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. <i>American Journal of Medicine</i> , 2008, 121, 748-757.	0.6	411

#	ARTICLE	IF	CITATIONS
649	Impact of Myocardial Function on Cystatin C Measurements in Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 394-399.	0.7	56
650	Prompt Reduction in Intra-Abdominal Pressure Following Large-Volume Mechanical Fluid Removal Improves Renal Insufficiency in Refractory Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 508-514.	0.7	162
651	Recent Insights Into the Role of Autoimmunity in Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2008, 14, 521-530.	0.7	42
652	Early and late effects of cardiac resynchronization therapy on forceâ€“frequency relation and contractility regulating gene expression in heart failure patients. <i>Heart Rhythm</i> , 2008, 5, 52-59.	0.3	64
653	Outcomes of Patients With Stable Heart Failure Undergoing Elective Noncardiac Surgery. <i>Mayo Clinic Proceedings</i> , 2008, 83, 280-288.	1.4	74
654	Mechanical dyssynchrony in advanced decompensated heart failure: Relation to hemodynamic responses to intensive medical therapy. <i>Heart Rhythm</i> , 2008, 5, 1105-1110.	0.3	10
655	Relation of mechanical dyssynchrony with underlying cardiac structure and performance in chronic systolic heart failure: implications on clinical response to cardiac resynchronization. <i>Europace</i> , 2008, 10, 1370-1374.	0.7	6
656	Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. <i>European Heart Journal</i> , 2008, 29, 2506-2513.	1.0	103
657	Rolofylline (KW-3902): a new adenosine A1-receptor antagonist for acute congestive heart failure. <i>Future Cardiology</i> , 2008, 4, 117-123.	0.5	7
658	Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome. <i>Core Evidence</i> , 2008, 3, 31-43.	4.7	3
659	Emerging drugs for acute and chronic heart failure: current and future developments. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 75-95.	1.0	5
660	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 2086-2096.	1.5	239
661	Exploring new drugs for heart failure: the case of urocortin. <i>European Heart Journal</i> , 2007, 28, 2561-2562.	1.0	3
662	Drug Insight: aldosterone-receptor antagonists in heart failureâ€“the journey continues. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 368-378.	3.3	17
663	Cardiac Resynchronization Therapy in New York Heart Association Class IV Heart Failure. <i>Circulation</i> , 2007, 115, 161-162.	1.6	7
664	Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal proâ€“B-type natriuretic peptide: A Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. <i>American Heart Journal</i> , 2007, 153, 36-41.	1.2	14
665	Peroxisome proliferatorâ€“activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularizationâ€“results of the PPAR Study. <i>American Heart Journal</i> , 2007, 154, 137-143.	1.2	31
666	Using echocardiography in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2007, 154, 1011-1020.	1.2	18

#	ARTICLE	IF	CITATIONS
667	Pharmacologic Therapy for Acute Heart Failure. <i>Cardiology Clinics</i> , 2007, 25, 539-551.	0.9	3
668	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure. <i>Circulation</i> , 2007, 116, e99-109.	1.6	234
669	Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2364-2370.	1.2	163
670	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2344-2351.	1.2	11
671	PPAR γ agonists: safety issues in heart failure. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 447-454.	2.2	36
672	Collaboration Among General Cardiologists, Heart Failure Specialists, and Electrophysiologists: What Are the Barriers?. <i>American Journal of Cardiology</i> , 2007, 99, S41-S44.	0.7	3
673	B-Type Natriuretic Peptide: A Critical Review. <i>Congestive Heart Failure</i> , 2007, 13, 48-52.	2.0	17
674	Glycemic control and treatment patterns in patients with heart failure. <i>Current Cardiology Reports</i> , 2007, 9, 242-247.	1.3	8
675	The impact of diabetes on heart failure: Opportunities for intervention. <i>Current Heart Failure Reports</i> , 2007, 4, 70-77.	1.3	5
676	A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus. <i>Vascular Health and Risk Management</i> , 2007, 3, 639-45.	1.0	0
677	Anemia in heart failure:current evidence and challenges. <i>Reviews in Cardiovascular Medicine</i> , 2007, 8, 78-86.	0.5	3
678	Natriuretic Peptides in Screening for Cardiac Dysfunction. <i>Heart Failure Clinics</i> , 2006, 2, 323-332.	1.0	1
679	Natriuretic Peptides in Valvular Heart Diseases. <i>Heart Failure Clinics</i> , 2006, 2, 345-352.	1.0	1
680	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2575-2583.	1.2	7
681	Changing Conduction Abnormalities in a Dialysis Patient With Fever. <i>Cardiology in Review</i> , 2006, 14, 158-160.	0.6	0
682	Plasma Myeloperoxidase Levels in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2006, 98, 796-799.	0.7	162
683	Vasopressin Receptor Antagonists in Heart Failure. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 177-184.	1.5	4
684	Do thiazolidinediones cause heart failure? A critical review.. <i>Cleveland Clinic Journal of Medicine</i> , 2006, 73, 390-397.	0.6	34

#	ARTICLE	IF	CITATIONS
685	New approaches to detect and manage edema and renal insufficiency in heart failure.. Cleveland Clinic Journal of Medicine, 2006, 73, S14-S14.	0.6	0
686	Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements. MedGenMed: Medscape General Medicine, 2006, 8, 62.	0.2	0
687	Glycemic control and treatment patterns in patients with heart failure. Heart Failure Monitor, 2006, 5, 10-4.	0.7	6
688	Case studies in advanced monitoring: OptiVol. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 1, S62-6.	0.5	0
689	Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure. Clinical Cornerstone, 2005, 7, S18-S24.	1.0	11
690	Neurohormonal Upregulation in Heart Failure. Heart Failure Clinics, 2005, 1, 1-9.	1.0	8
691	Vasopressin receptor antagonists in the management of acute heart failure. Expert Opinion on Investigational Drugs, 2005, 14, 593-600.	1.9	4
692	Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure. Mayo Clinic Proceedings, 2005, 80, 1623-1630.	1.4	30
693	Why do patients fail to receive β -blockers for chronic heart failure over time? A "real-world" single-center, 2-year follow-up experience of β -blocker therapy in patients with chronic heart failure. American Heart Journal, 2005, 149, 921-926.	1.2	26
694	The Difficult Task of Evaluating How to Monitor Patients With Heart Failure. Journal of Cardiac Failure, 2005, 11, 422-424.	0.7	12
695	The Year in Heart Failure. Journal of the American College of Cardiology, 2005, 46, 2125-2133.	1.2	10
696	Vasopressin Receptor Antagonists. JAMA - Journal of the American Medical Association, 2004, 291, 2017.	3.8	24
697	Plasma B-Type Natriuretic Peptide Levels Predict Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery. Circulation, 2004, 110, 124-127.	1.6	131
698	Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade. Circulation, 2004, 110, 3618-3620.	1.6	7
699	Encephalitis Owing to Human Herpesvirus-6 after Cardiac Transplant. American Journal of Transplantation, 2004, 4, 1200-1203.	2.6	59
700	Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Progress in Cardiovascular Diseases, 2004, 47, 196-206.	1.6	28
701	Coronary revascularization for treatment of heart failure: optimal patient selection. ACC Current Journal Review, 2004, 13, 35-39.	0.1	0
702	Evolving concepts in left ventricular systolic and diastolic remodeling: Implications for therapy. Current Cardiology Reports, 2004, 6, 200-204.	1.3	1

#	ARTICLE	IF	CITATIONS
703	Ischemic heart disease and congestive heart failure in diabetic patients. Medical Clinics of North America, 2004, 88, 1037-1061.	1.1	24
704	Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology, 2004, 43, 542-548.	1.2	26
705	Insulin resistance in idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology, 2004, 44, 78-81.	1.2	107
706	Does the underlying etiology influence plasma B-type natriuretic peptide levels of patients with isolated chronic aortic regurgitation and preserved left ventricular function?. Journal of Cardiac Failure, 2004, 10, S52.	0.7	1
707	Patterns of β -blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. American Heart Journal, 2004, 147, 79-83.	1.2	49
708	Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high-versus low-dose enalapril in advanced heart failure. American Heart Journal, 2004, 148, 889-894.	1.2	18
709	Drugs Blocking the Renin-Angiotensin-Aldosterone System. , 2004, , 227-241.		0
710	Spironolactone in chronic heart failure: all β ™s well that ends well**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2003, 41, 215-216.	1.2	9
711	Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. Journal of the American College of Cardiology, 2003, 41, 1394-1398.	1.2	157
712	Is the tolerability of long-term thiazolidinedione therapy overstated? Reply. Journal of the American College of Cardiology, 2003, 42, 1334-1335.	1.2	1
713	β -Blockers and reverse remodeling: What are the implications?. American Heart Journal, 2003, 145, 200-202.	1.2	16
714	Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure. Circulation, 2003, 108, 2964-2966.	1.6	213
715	Trends and Treatment of Heart Failure Developing After Acute Myocardial Infarction. The American Heart Hospital Journal, 2003, 1, 216-218.	0.2	5
716	Novel pharmacological treatments for heart failure. Expert Opinion on Investigational Drugs, 2003, 12, 1791-1801.	1.9	12
717	In heart failure, all beta-blockers are not necessarily equal.. Cleveland Clinic Journal of Medicine, 2003, 70, 1081-1087.	0.6	2
718	Pathophysiology of congestive heart failure. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 2, S14-20.	0.5	21
719	Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. Journal of the American College of Cardiology, 2002, 39, 70-78.	1.2	85
720	Cardiac troponins in renal insufficiency. Journal of the American College of Cardiology, 2002, 40, 2065-2071.	1.2	353

#	ARTICLE	IF	CITATIONS
721	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. American Journal of Cardiology, 2002, 90, 1198-1203.	0.7	10
722	CARDIOMYOPATHY AND HEART FAILURE IN DIABETES. Endocrinology and Metabolism Clinics of North America, 2001, 30, 1031-1046.	1.2	19
723	POLYPHARMACY OF HEART FAILURE. Cardiology Clinics, 2001, 19, 583-596.	0.9	14
724	The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure. Archives of Internal Medicine, 2001, 161, 667.	4.3	25
725	Clinical Trials of Carvedilol in Heart Failure. Heart Failure Reviews, 1999, 4, 79-88.	1.7	6
726	Biomarkers for Risk Stratification in Patients with Heart Failure. , 0, , 116-139.		0
727	Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. , 0, .		1
728	Novel Therapies in Heart Failure. , 0, , 44-68.		0
729	Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis. Frontiers in Physiology, 0, 13, .	1.3	1